Literature DB >> 11106669

HER2 in prostate cancer--a viable target or innocent bystander?

H I Scher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11106669     DOI： 10.1093/jnci/92.23.1866

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

1.  Development of a peptide-drug conjugate for prostate cancer therapy.

Authors:  Wanyi Tai; Ravi S Shukla; Bin Qin; Benyi Li; Kun Cheng
Journal:  Mol Pharm       Date:  2011-05-03       Impact factor: 4.939

2.  Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.

Authors:  Shang-Ru Wu; Tai-Shan Cheng; Wen-Chi Chen; Hsin-Yi Shyu; Chun-Jung Ko; Hsiang-Po Huang; Chen-Hsin Teng; Chia-Hau Lin; Michael D Johnson; Chen-Yong Lin; Ming-Shyue Lee
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

3.  Using circulating tumor cells to advance precision medicine in prostate cancer.

Authors:  Giuseppe Galletti; Daniel Worroll; David M Nanus; Paraskevi Giannakakou
Journal:  J Cancer Metastasis Treat       Date:  2017-09-27

Review 4.  The role of HER2 in cancer therapy and targeted drug delivery.

Authors:  Wanyi Tai; Rubi Mahato; Kun Cheng
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

5.  Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.

Authors:  Kimmo J Savinainen; Outi R Saramäki; Marika J Linja; Ola Bratt; Teuvo L J Tammela; Jorma J Isola; Tapio Visakorpi
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 6.  Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer.

Authors:  Quanxia Lv; Ziyuan Meng; Yuanyuan Yu; Feng Jiang; Daogang Guan; Chao Liang; Junwei Zhou; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-12-14       Impact factor: 5.923

7.  Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours.

Authors:  P A Sotiropoulou; S A Perez; E G Iliopoulou; I Missitzis; V Voelter; H Echner; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.